Concepts (150)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinal Diseases | 3 | 2023 | 47 | 1.540 |
Why?
|
| Diabetic Retinopathy | 2 | 2023 | 112 | 1.260 |
Why?
|
| PPAR alpha | 3 | 2025 | 44 | 1.200 |
Why?
|
| HSP90 Heat-Shock Proteins | 7 | 2018 | 61 | 1.170 |
Why?
|
| Membrane Proteins | 3 | 2025 | 486 | 1.110 |
Why?
|
| Drug Design | 6 | 2020 | 63 | 1.090 |
Why?
|
| Isoquinolines | 1 | 2025 | 15 | 0.940 |
Why?
|
| Interferons | 1 | 2025 | 70 | 0.910 |
Why?
|
| Structure-Activity Relationship | 7 | 2025 | 209 | 0.840 |
Why?
|
| Gene Expression Regulation, Bacterial | 3 | 2022 | 158 | 0.840 |
Why?
|
| Oxazolidinones | 1 | 2022 | 4 | 0.760 |
Why?
|
| Vascular Diseases | 2 | 2020 | 68 | 0.750 |
Why?
|
| Macular Degeneration | 1 | 2023 | 86 | 0.730 |
Why?
|
| Spores, Bacterial | 1 | 2021 | 50 | 0.690 |
Why?
|
| Molecular Structure | 7 | 2025 | 246 | 0.680 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2020 | 4 | 0.670 |
Why?
|
| Antineoplastic Agents | 5 | 2016 | 686 | 0.670 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 216 | 0.660 |
Why?
|
| Benzylamines | 1 | 2020 | 19 | 0.640 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 137 | 0.610 |
Why?
|
| Carbazoles | 1 | 2019 | 6 | 0.600 |
Why?
|
| Depsipeptides | 1 | 2018 | 5 | 0.580 |
Why?
|
| Endopeptidase Clp | 1 | 2018 | 9 | 0.580 |
Why?
|
| Bacterial Proteins | 2 | 2022 | 499 | 0.560 |
Why?
|
| Quinolines | 1 | 2018 | 35 | 0.550 |
Why?
|
| Triazines | 2 | 2014 | 11 | 0.530 |
Why?
|
| Proteolysis | 4 | 2025 | 59 | 0.520 |
Why?
|
| HSP70 Heat-Shock Proteins | 2 | 2018 | 45 | 0.490 |
Why?
|
| Indolizines | 1 | 2016 | 1 | 0.490 |
Why?
|
| Spiro Compounds | 1 | 2016 | 5 | 0.480 |
Why?
|
| Endopeptidases | 1 | 2016 | 20 | 0.480 |
Why?
|
| Models, Molecular | 5 | 2020 | 453 | 0.460 |
Why?
|
| Biological Products | 1 | 2016 | 67 | 0.450 |
Why?
|
| Amidines | 1 | 2014 | 8 | 0.420 |
Why?
|
| Bleomycin | 1 | 2014 | 11 | 0.420 |
Why?
|
| Dipeptides | 1 | 2014 | 22 | 0.410 |
Why?
|
| Humans | 19 | 2025 | 29078 | 0.400 |
Why?
|
| Animals | 10 | 2025 | 10756 | 0.390 |
Why?
|
| Pyrimidines | 1 | 2014 | 128 | 0.380 |
Why?
|
| Gram-Negative Bacteria | 2 | 2022 | 62 | 0.350 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2025 | 612 | 0.330 |
Why?
|
| Drug Discovery | 2 | 2020 | 37 | 0.320 |
Why?
|
| Macrolides | 2 | 2009 | 19 | 0.320 |
Why?
|
| Virulence | 2 | 2021 | 154 | 0.310 |
Why?
|
| Membrane Glycoproteins | 3 | 2016 | 149 | 0.310 |
Why?
|
| Amides | 1 | 2009 | 19 | 0.300 |
Why?
|
| Protein Conformation | 4 | 2016 | 259 | 0.300 |
Why?
|
| Drug Resistance | 1 | 2009 | 42 | 0.290 |
Why?
|
| Ligands | 2 | 2020 | 178 | 0.290 |
Why?
|
| Anti-Bacterial Agents | 4 | 2022 | 538 | 0.290 |
Why?
|
| Oxidative Stress | 1 | 2010 | 680 | 0.230 |
Why?
|
| Prodrugs | 1 | 2025 | 31 | 0.230 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2022 | 150 | 0.230 |
Why?
|
| Cell Line | 2 | 2020 | 701 | 0.220 |
Why?
|
| Endoplasmic Reticulum-Associated Degradation | 2 | 2016 | 4 | 0.220 |
Why?
|
| Cytoskeletal Proteins | 2 | 2016 | 42 | 0.210 |
Why?
|
| Endoplasmic Reticulum | 2 | 2016 | 80 | 0.210 |
Why?
|
| Glycoproteins | 2 | 2016 | 124 | 0.200 |
Why?
|
| Nucleotidyltransferases | 1 | 2023 | 7 | 0.200 |
Why?
|
| Drug Delivery Systems | 1 | 2025 | 236 | 0.190 |
Why?
|
| Linezolid | 1 | 2022 | 4 | 0.190 |
Why?
|
| Eye Proteins | 2 | 2016 | 207 | 0.190 |
Why?
|
| Uropathogenic Escherichia coli | 1 | 2022 | 5 | 0.180 |
Why?
|
| Bortezomib | 1 | 2021 | 23 | 0.180 |
Why?
|
| Escherichia coli Infections | 1 | 2022 | 45 | 0.180 |
Why?
|
| Urinary Tract Infections | 1 | 2022 | 39 | 0.180 |
Why?
|
| Gene Editing | 1 | 2021 | 27 | 0.170 |
Why?
|
| Protein Isoforms | 1 | 2021 | 119 | 0.170 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2022 | 72 | 0.170 |
Why?
|
| Benzoquinones | 3 | 2009 | 26 | 0.170 |
Why?
|
| Lactams, Macrocyclic | 3 | 2009 | 26 | 0.170 |
Why?
|
| Clostridium Infections | 1 | 2021 | 67 | 0.170 |
Why?
|
| Rats | 2 | 2025 | 1594 | 0.170 |
Why?
|
| Escherichia coli Proteins | 1 | 2022 | 118 | 0.170 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 74 | 0.160 |
Why?
|
| Streptozocin | 1 | 2020 | 11 | 0.160 |
Why?
|
| Escherichia coli | 1 | 2022 | 340 | 0.160 |
Why?
|
| Prospective Studies | 1 | 2023 | 1286 | 0.150 |
Why?
|
| Capillary Permeability | 1 | 2020 | 56 | 0.150 |
Why?
|
| Mutation | 2 | 2021 | 873 | 0.150 |
Why?
|
| Phenotype | 1 | 2021 | 688 | 0.150 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2018 | 133 | 0.140 |
Why?
|
| Isoenzymes | 1 | 2018 | 88 | 0.140 |
Why?
|
| Inflammation | 1 | 2023 | 669 | 0.140 |
Why?
|
| Disease Models, Animal | 2 | 2022 | 1522 | 0.140 |
Why?
|
| Eye Diseases | 1 | 2018 | 31 | 0.140 |
Why?
|
| Cycloaddition Reaction | 2 | 2014 | 4 | 0.130 |
Why?
|
| Biomarkers | 1 | 2020 | 787 | 0.130 |
Why?
|
| Proteomics | 1 | 2018 | 197 | 0.130 |
Why?
|
| Acetanilides | 1 | 2016 | 4 | 0.120 |
Why?
|
| Hydroxybenzoates | 1 | 2016 | 6 | 0.120 |
Why?
|
| Receptors, GABA-A | 1 | 2016 | 18 | 0.120 |
Why?
|
| Benzoates | 1 | 2016 | 30 | 0.120 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2016 | 55 | 0.120 |
Why?
|
| Imidazoles | 1 | 2016 | 63 | 0.120 |
Why?
|
| Catalysis | 1 | 2016 | 134 | 0.120 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2016 | 72 | 0.120 |
Why?
|
| HEK293 Cells | 2 | 2016 | 202 | 0.120 |
Why?
|
| Mice | 3 | 2022 | 4845 | 0.110 |
Why?
|
| Adenosine Triphosphate | 2 | 2018 | 121 | 0.110 |
Why?
|
| Stereoisomerism | 2 | 2014 | 45 | 0.100 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2013 | 22 | 0.100 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2011 | 103 | 0.100 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2012 | 23 | 0.090 |
Why?
|
| Indoles | 1 | 2013 | 111 | 0.090 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2012 | 19 | 0.090 |
Why?
|
| Drosophila | 1 | 2012 | 32 | 0.090 |
Why?
|
| Toll-Like Receptors | 1 | 2012 | 22 | 0.090 |
Why?
|
| Autophagy | 1 | 2012 | 77 | 0.090 |
Why?
|
| Protein Transport | 1 | 2012 | 158 | 0.090 |
Why?
|
| Novobiocin | 1 | 2011 | 16 | 0.090 |
Why?
|
| DNA | 1 | 2013 | 378 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 484 | 0.080 |
Why?
|
| Bridged Bicyclo Compounds | 1 | 2009 | 21 | 0.080 |
Why?
|
| Benzene Derivatives | 1 | 2009 | 7 | 0.080 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 166 | 0.080 |
Why?
|
| Protein Binding | 3 | 2018 | 667 | 0.080 |
Why?
|
| Hydrolysis | 1 | 2009 | 60 | 0.070 |
Why?
|
| Adenosine Triphosphatases | 1 | 2009 | 50 | 0.070 |
Why?
|
| Crystallography, X-Ray | 2 | 2018 | 223 | 0.060 |
Why?
|
| Biological Availability | 1 | 2025 | 44 | 0.060 |
Why?
|
| Emulsions | 1 | 2025 | 26 | 0.060 |
Why?
|
| Cell Proliferation | 3 | 2016 | 827 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2025 | 191 | 0.060 |
Why?
|
| Binding Sites | 2 | 2016 | 355 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2025 | 554 | 0.050 |
Why?
|
| Cell Line, Tumor | 3 | 2013 | 1360 | 0.050 |
Why?
|
| Female | 3 | 2022 | 15740 | 0.050 |
Why?
|
| Blotting, Western | 2 | 2016 | 515 | 0.050 |
Why?
|
| Permeability | 1 | 2022 | 61 | 0.050 |
Why?
|
| Virulence Factors | 1 | 2022 | 45 | 0.040 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2022 | 48 | 0.040 |
Why?
|
| Salmonella typhimurium | 1 | 2022 | 69 | 0.040 |
Why?
|
| Protein Kinases | 1 | 2022 | 163 | 0.040 |
Why?
|
| Cell Membrane | 1 | 2022 | 268 | 0.040 |
Why?
|
| Molecular Conformation | 1 | 2018 | 67 | 0.030 |
Why?
|
| Male | 2 | 2025 | 14049 | 0.030 |
Why?
|
| Dogs | 1 | 2018 | 510 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2016 | 33 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2016 | 105 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2016 | 71 | 0.030 |
Why?
|
| Glaucoma | 1 | 2016 | 53 | 0.030 |
Why?
|
| Wound Healing | 1 | 2016 | 126 | 0.030 |
Why?
|
| Cell Movement | 1 | 2016 | 377 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2013 | 34 | 0.030 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2013 | 46 | 0.030 |
Why?
|
| Solubility | 1 | 2013 | 73 | 0.030 |
Why?
|
| Pyrroles | 1 | 2013 | 36 | 0.020 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2013 | 72 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2013 | 181 | 0.020 |
Why?
|